Syndax Pharmaceuticals Q2 2026 Earnings Report

Syndax Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.45
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Syndax Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $79.36 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Syndax Pharmaceuticals Announcement Details

• Quarter: Q2 2026
• Date: 8/4/2026
• Time: After Market Closes
• Conference Call Date: Tuesday, August 4, 2026
• Conference Call Time: 4:30PM ET

Syndax Pharmaceuticals (NASDAQ:SNDX) is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications. Entinostat is currently in Phase 3 development in combination with pembrolizumab for patients with hormone receptor-positive, HER2-negative advanced breast cancer. Syndax’s pipeline also includes SNDX-5613 (revumenib), a menin inhibitor targeting acute leukemias harboring MLL rearrangements or NPM1 mutations, which is advancing through Phase 2 clinical trials. In addition to these core programs, Syndax is exploring combination strategies to maximize clinical benefit and address resistance mechanisms.

The company was founded in 2002 and has cultivated collaborations with leading academic institutions and industry partners to accelerate development and broaden the reach of its therapies. Syndax operates primarily in the United States but plans to expand its global footprint through strategic partnerships and licensing agreements. Under the leadership of President and Chief Executive Officer Daniel A. Swisher and Chief Financial Officer Wolfgang R. Grosse, Syndax continues to build a pipeline designed to deliver meaningful improvements in outcomes for cancer patients worldwide.